Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | PDE8B | O95263 | 1/20 | 0.32 |
| ▸ | RHEB | Q15382 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19980339 | 0.87 | PDE8B (0.34) | PDE8BGSK3BKCNH2TLR7FFAR2 | |
| SCHEMBL15964620 | 0.83 | KDM5B (0.40) | RHEB | |
| SCHEMBL17324406 | 0.82 | LMNA (0.35) | TLR7MAPK1 | |
| SCHEMBL15964621 | 0.82 | KDM5B (0.41) | RHEB | |
| SCHEMBL17321277 | 0.76 | PDE8B (0.32) | PDE8BTLR7 | |
| SCHEMBL15964836 | 0.69 | CHEK2 (0.39) | — | |
| SCHEMBL17321291 | 0.69 | HTR3A (0.32) | PDE8BTLR7 | |
| SCHEMBL21798836 | 0.66 | HTR2B (0.39) | — | |
| SCHEMBL22048751 | 0.66 | ADORA2A (0.34) | — | |
| SCHEMBL12080316 | 0.66 | SLC6A12 (0.39) | FEN1PDE8B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508484-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3342771-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| EP-3375780-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| US-20190262356-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-29 | — | — | US | disclosed |
| EP-3508484-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-20190201413-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-10292987-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| EP-3342771-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2018-07-04 | — | — | EP | disclosed |
| US-20180098998-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| EP-2956452-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-03-21 | — | — | EP | disclosed |
| US-20170183332-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-29 | — | — | US | disclosed |
| US-9624202-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-9556152-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| US-20170008878-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-12 | — | — | US | disclosed |
| US-20150353533-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-10 | — | — | US | disclosed |
| WO-2014125444-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183332-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | FEN1 4326/4885PDE8B 1750/4885RHEB 750/4885 |
| US-20190201413-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | FEN1 4326/4885PDE8B 1750/4885RHEB 750/4885 |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | FEN1 4326/4885PDE8B 1750/4885RHEB 750/4885 |
| US-20190262356-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | FEN1 4326/4885PDE8B 1750/4885RHEB 750/4885 |
| US-20170008878-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | FEN1 4326/4885PDE8B 1750/4885RHEB 750/4885 |
| US-20180098998-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | FEN1 4326/4885PDE8B 1750/4885RHEB 750/4885 |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | FEN1 4326/4885PDE8B 1750/4885RHEB 750/4885 |
| US-20150353533-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP3K3 | FEN1 4325/4885PDE8B 1815/4885RHEB 745/4885 |
| US-10292987-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | FEN1 4326/4885PDE8B 1750/4885RHEB 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.